Trials / Completed
CompletedNCT03180528
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Kavita Sarin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. Overall response rate of basal cell carcinoma (BCC) in subjects at 6 weeks. SECONDARY OBJECTIVES: I. Suppression of GLI1 (glioma-associated oncogene) expression in treated BCCs as compared with baseline. II. Safety assessment of Remetinostat after 6 weeks of topical treatment. OUTLINE: Tumors receive Remetinostat topically three times per day (TID) for 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for at least 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remetinostat | Applied topically under bandage occlusion |
Timeline
- Start date
- 2018-07-07
- Primary completion
- 2020-07-07
- Completion
- 2020-12-31
- First posted
- 2017-06-08
- Last updated
- 2021-06-08
- Results posted
- 2021-01-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03180528. Inclusion in this directory is not an endorsement.